These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6644972)

  • 1. Heroin-associated nephropathy. A nationwide problem.
    Cunningham EE; Zielezny MA; Venuto RC
    JAMA; 1983 Dec; 250(21):2935-6. PubMed ID: 6644972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of heroin abuse on a regional end-stage renal disease program.
    Zielezny MA; Cunningham EE; Venuto RC
    Am J Public Health; 1980 Aug; 70(8):829-31. PubMed ID: 7416344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA associations in heroin-associated nephropathy.
    Haskell LP; Glicklich D; Senitzer D
    Am J Kidney Dis; 1988 Jul; 12(1):45-50. PubMed ID: 3389354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heroin nephropathy. A clinicopathologic and epidemiologic study.
    Cunningham EE; Brentjens JR; Zielezny MA; Andres GA; Venuto RC
    Am J Med; 1980 Jan; 68(1):47-53. PubMed ID: 7350805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why does uremia in heroin abusers occur predominantly among blacks?
    Friedman EA; Rao TK
    JAMA; 1983 Dec; 250(21):2965-6. PubMed ID: 6644974
    [No Abstract]   [Full Text] [Related]  

  • 6. X. The economic cost of ESRD and Medicare spending for alternative modalities of treatment.
    Am J Kidney Dis; 1999 Aug; 34(2 Suppl 1):S124-39. PubMed ID: 10431009
    [No Abstract]   [Full Text] [Related]  

  • 7. The charges for ESRD treatment of diabetics.
    Smith DG; Harlan LC; Hawthorne VM
    J Clin Epidemiol; 1989; 42(2):111-8. PubMed ID: 2493073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors determining the rate of referral, transplantation, and survival on dialysis in women with ESRD.
    McCauley J; Irish W; Thompson L; Stevenson J; Lockett R; Bussard R; Washington M
    Am J Kidney Dis; 1997 Dec; 30(6):739-48. PubMed ID: 9398116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. License to plunder or to paint.
    Lundberg GD
    JAMA; 1983 Dec; 250(21):2966-7. PubMed ID: 6358553
    [No Abstract]   [Full Text] [Related]  

  • 10. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era.
    Abbott KC; Hypolite I; Welch PG; Agodoa LY
    J Nephrol; 2001; 14(5):377-83. PubMed ID: 11730270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study.
    Moreno Velásquez I; Tribaldos Causadias M; Valdés R; Gómez B; Motta J; Cuero C; Herrera-Ballesteros V
    BMJ Open; 2019 May; 9(5):e027229. PubMed ID: 31133590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and direct medical costs of end-stage renal disease in patients with type 2 diabetes mellitus in Switzerland for 2001.
    Sandoz MS; Ess SM; Keusch GW; Schwenkglenks M; Szucs TD
    Swiss Med Wkly; 2004 Aug; 134(31-32):448-58. PubMed ID: 15389348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access.
    Lee H; Manns B; Taub K; Ghali WA; Dean S; Johnson D; Donaldson C
    Am J Kidney Dis; 2002 Sep; 40(3):611-22. PubMed ID: 12200814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social Risk and Dialysis Facility Performance in the First Year of the ESRD Treatment Choices Model.
    Koukounas KG; Thorsness R; Patzer RE; Wilk AS; Drewry KM; Mehrotra R; Rivera-Hernandez M; Meyers DJ; Kim D; Trivedi AN
    JAMA; 2024 Jan; 331(2):124-131. PubMed ID: 38193961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD.
    Yan G; Cheung AK; Ma JZ; Yu AJ; Greene T; Oliver MN; Yu W; Norris KC
    Clin J Am Soc Nephrol; 2013 Apr; 8(4):610-8. PubMed ID: 23493380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dilemmas of patient treatment for end-stage renal disease.
    Schmidt RW; Blumenkrantz M; Wiegmann TB
    Am J Kidney Dis; 1983 Jul; 3(1):37-47. PubMed ID: 6346866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement.
    Owen WF
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S76-80. PubMed ID: 12819307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal consequences of narcotic abuse.
    Sreepada Rao TK; Nicastri AD; Friedman EA
    Adv Nephrol Necker Hosp; 1977; 7():261-90. PubMed ID: 27085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD.
    Ishani A; Guo H; Arneson TJ; Gilbertson DT; Mau LW; Li S; Dunning S; Collins AJ
    J Am Soc Nephrol; 2009 Jul; 20(7):1607-13. PubMed ID: 19389846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.